Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study Weber PA; Wirostko BM; Xu X; Goss TF; Zlateva GBMC Ophthalmol 2010[Feb]; 10 (ä): 2BACKGROUND: Studies have shown that early detection and treatment of neovascular age-related macular degeneration (NV-AMD) can delay vision loss and blindness. The objective of this study was to evaluate the efficacy/safety of intravitreal pegaptanib sodium monotherapy in treatment-naive subjects with newly diagnosed NV-AMD and to gain insight into characteristics of lesions treated in community-based practices. METHODS: From seven private US practices, charts were retrospectively reviewed on 73 subjects with previously untreated subfoveal choroidal NV-AMD treated with their first dose of pegaptanib monotherapy on/after 4/1/2005 through 6/5/2006, receiving > or =4 treatments at 6-week intervals over 21 weeks. Primary endpoint: mean visual acuity (VA) change from baseline to month 6. RESULTS: 75% of lesions were occult, and 82% were subfoveal. From baseline to month 6, mean VA change was -0.68 lines; 58% and 16% gained > or =0 and > or =3 lines of VA, and 70% were responders (<3 lines lost). In 35 subjects with early disease, 80% were responders with a mean gain of 0.46 lines. CONCLUSION: Pegaptanib is effective in real-world patients with treatment-naive NV-AMD in uncontrolled community-based retina practices.|Aged[MESH]|Aged, 80 and over[MESH]|Aptamers, Nucleotide/*administration & dosage/adverse effects[MESH]|Choroidal Neovascularization/drug therapy/physiopathology[MESH]|Community Medicine[MESH]|Drug Administration Schedule[MESH]|Exudates and Transudates/*metabolism[MESH]|Female[MESH]|Fovea Centralis[MESH]|Humans[MESH]|Injections, Intraocular[MESH]|Macular Degeneration/*drug therapy/*metabolism/physiopathology[MESH]|Male[MESH]|Medical Records[MESH]|Middle Aged[MESH]|Professional Practice[MESH]|Retrospective Studies[MESH]|Treatment Outcome[MESH]|United States[MESH]|Vascular Endothelial Growth Factor A/*antagonists & inhibitors[MESH]|Visual Acuity/drug effects[MESH]|Vitreous Body[MESH] |
